Description

Gujarat Kidney and Super Speciality Limited added to BSE IPO Index effective January 1, 2026, and Dachepalli Publishers Limited added to BSE SME IPO Index effective December 31, 2025.

Summary

BSE announces the addition of two newly listed companies to its indices. Gujarat Kidney and Super Speciality Limited (ticker: 544666) will be added to the BSE IPO Index effective January 1, 2026, following its listing on December 30, 2025. Dachepalli Publishers Limited (ticker: 544667) will be added to the BSE SME IPO Index effective December 31, 2025, following its listing on the SME platform on December 30, 2025.

Key Points

  • Gujarat Kidney and Super Speciality Limited (544666) listed on BSE on December 30, 2025
  • Stock will be added to BSE IPO Index at market open on January 1, 2026
  • Dachepalli Publishers Limited (544667) listed on BSE SME platform on December 30, 2025
  • Stock will be added to BSE SME IPO Index at market open on December 31, 2025
  • Actions included in end-of-day corporate action file (*.SDE)
  • References prior notices 20251229-15 and 20251229-31

Regulatory Changes

No regulatory changes. This is a standard index reconstitution announcement following new listings.

Compliance Requirements

No specific compliance requirements. Market participants should note the index additions for portfolio management and index tracking purposes.

Important Dates

  • December 30, 2025: Listing date for both Gujarat Kidney and Super Speciality Limited and Dachepalli Publishers Limited
  • December 31, 2025: Dachepalli Publishers Limited added to BSE SME IPO Index (at market open)
  • January 1, 2026: Gujarat Kidney and Super Speciality Limited added to BSE IPO Index (at market open)

Impact Assessment

Minimal market impact. This is a routine administrative action affecting index composition following new IPO listings. Index funds and ETFs tracking the BSE IPO Index and BSE SME IPO Index will need to adjust their holdings accordingly. The additions are procedural in nature with no impact on trading rules or market operations.

Impact Justification

Routine index addition for newly listed companies; no trading restrictions or compliance changes.